The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

Francesco Passiglia, Patrizia Diana, Antonio Russo, Angela Listi', Marco Giallombardo, Girolamo Cirrincione, Christian Caglevic, Marco Giallombardo, Rafael Caparica, Rafael Caparica, Christian Rolfo, Luis E. Raez, Elisa Giovannetti

Risultato della ricerca: Article

21 Citazioni (Scopus)


Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identifiedin several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potentialrole as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinicaldevelopment of a new class of compounds blocking the NTRK molecular pathway, which are currentlyundner early clinical investigation.Area covered: This review describes the biology of the NTRK pathway and its molecular alterations inlung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, whichhave shown very promising activity in early phase I studies.Expert opinion: Among the several NTRK-inhibitors, entrectinib and LOXO-101 are those in moreadvanced stage of clinical development. Both agents have shown encouraging activity along with atolerable safety profile in patients with different solid tumors harboring NTRK-fusions, emerging as newpromising therapeutic options for molecularly selected patients with advanced Trk-driven lung cancers.Results from ongoing phase II basket trials are eagerly awaited.
Lingua originaleEnglish
Numero di pagine9
RivistaExpert Opinion on Investigational Drugs
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Entra nei temi di ricerca di 'The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer'. Insieme formano una fingerprint unica.

  • Cita questo